PRIMUS 008: A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb

We are pleased to inform you that Cambridge University Hospitals Foundation Trust (Addenbrooke’s Hospital) is now open for recruitment and taking referrals for the NIHR Portfolio PemOla trial!

Please send referrals to the PI: bristi.basu@nhs.net, or PemOla CI: philippa.corrie@nhs.net, OR for more information, contact cuh.pemola@nhs.net

Patient Eligibility:

  • Stage 4 Pancreatic adenocarcinoma
  • 1st or 2nd line systemic therapy
    • AND
  • a specific biomarker (identified OUTSIDE of the clinical trial):
  • Tumour Mutation Burden (TMB) >4 mutations/Mb
    • OR
  • A dMMR gene mutation
    • OR
  • MSI-H (dMMR protein identified by IHC)

    • Biomarker testing: all routes are OK!